Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Latest News
PBAC guidelines: minister should intervene
Reimbursement: Medicines innovation in Australia will be at risk unless there is ministerial intervention on controversial aspects of the draft PBAC guidelines says MSD's Phil Kearney.
PBS savings of $160m go begging
Reimbursement: Putting non-dispensing pharmacists into medical practices could save the PBS budget $160m a year, doctors say.
PBS up 14 per cent in 12 months
Reimbursement: PBS figures for the full financial year show that spending is up by 14% and the reason is clear.
Mayne tipped to join global generic A-list
Companies: Mayne Pharma's $888 million generic drug portfolio acquisition, courtesy of the Teva/Allergan deal, has seen its value rocket to $2.5 billion with the pharmaco now tipped to be listed among the top 100 ASX-listed stocks by the end of 2016.
Pharma growth plan gets slim funding
Industry Support: The government body established to drive innovation in the pharma and med tech sectors has just $15.6m out of a $248m budget for projects over the next four years.
TGA to examine clinical trial guidance
Regulation: The TGA is keeping an eye on clinical trial guidelines after the European Medicines Agency released a concept paper detailing possible changes.
Most Popular
Four top pharmacos in HR awards
Employment: Four of the nation's top pharma companies are among those named as finalists in this year's Australian HR Awards.
New boss for Merck Serono
Leadership: After a five month wait, Merck Serono has announced the appointment of a new general manager for Australia and New Zealand.
October PBS price cut damage revealed
Reimbursement: The first round of PBS disclosure-based price cuts without originators will average 24 per cent, range up to 82 per cent and affect close to 330 items, the Department of Health has revealed.
Roche city-bound for new HQ
On the Move: Roche appears to have found a new home for its corporate head office, signing a 'letter of intent' for new premises in Sydney's burgeoning Barangaroo precinct.
Top ten pharma issues for new govt
Questions over whether Sussan Ley will retain her health portfolio should be answered today when Prime Minister Malcolm Turnbull announces his post-election ministry but, whether she retains the job or not, Aussie pharma has a host of outstanding issues that urgently need addressing.
PBAC falling behind with patients
Medicines Access: David Grainger, Eli Lilly senior director of Global Public Policy, says Australia's HTA system is falling behind similar jurisdictions in gathering and integrating patient input.
Amneal takes aim at Lilly's Strattera
Generics: Amneal says it will be the first generic company to list against Lilly's multi-million dollar ADHD drug, hitting the PBS on August 1.
Local agencies spared in GSK marketing reboot
Marketing: Australia has been spared any immediate impact as GSK Consumer announces a global restructure of marketing, PR and advertising agencies.
Biogen posts successful quarter, CEO goes
Companies: Biogen global CEO George Scangos announced his exit from the company as it reported a 12% boost to revenues this quarter.
MA welcomes health shadows
Policy: Medicines Australia has welcomed the re-appointment of Catherine King as Labor's health spokesperson, saying the sector will work with the opposition as well as the government.
Bayer retains Pharmac contract
Medicines Access: Some patients in NZ will have ongoing subsidised access to Bayer's contraceptive Mirena thanks to a sole supply contract but it isn't all smooth sailing.
Approvals Action
TGA approves Enbrel competitor
The TGA has approved MSD's Brenzys, its biosimilar competitor for Pfizer's blockbuster Enbrel.
Pipeline Monitor
Opdivo in line for label expansion
BMS's Opdivo is on track to add another cancer to its growing list of approvals.
Company Snapshot
Pfizer: the giant powers on
Pfizer's Australian operations go under the microscope.
FREE Content
Events & Conferences
Pharma in Focus Jobs